CONTENTS:

• COVID-19 Vaccination in Children and Young Adults with Pre-Existing ITP: Data from The ITP Natural History Study Registry
• IVIG Use and The Risk of Contracting SARS-CoV-2 in Patients with ITP: Data from The ITP Natural History Study Registry

CONTENTS:

• Long-Term Risk of Developing Immune Thrombocytopenia (ITP) or Another Blood Disorder in Adults Who Have Mildly Low Platelet Counts
• Immune Thrombocytopenia and Pregnancy

CONTENTS:

• Risk Factors for Systemic Lupus Erythematous (SLE) In Patients with Immune Thrombocytopenia (ITP)
• Using Recombinant Human Thrombopoietin (rhTPO) To Glucocorticoids in The Treatment of Patients with Immune Thrombocytopenia (ITP)

CONTENTS:

The European Hematology Association (EHA) held its first hybrid meeting since the start of the pandemic. The in-person meeting took place June 9-12, 2022, in Vienna, Austria. The EHA 2022 Congress provided an opportunity for expert knowledge and experience gained worldwide to come together in one space. Several cutting-edge posters and oral presentations were presented with a focus on immune thrombocytopenia (ITP). The following summaries are from three abstracts presented at EHA.

• Preliminary Analysis of the TAPER Trial In ITP patients: Maintenance Following Eltrombopag Use
• Long-Term Follow- Up with Rilzabrutinib in ITP Patients

CONTENTS:

• Comparison of Rituximab Response in Adults with Difficult to Treat ITP Due to the Presence of an Accessory Spleen
• Diagnosis Immune Thrombocytopenia (ITP) Including Secondary ITP, and Selection of Second Line Therapy

CONTENTS:

• Treatment of Pediatric Immune Thrombocytopenia (ITP): A Systematic Review and Meta-Analysis of Prospective Clinical Trials
• Frequency and Utility of Bone Marrow Examination in Relapsed/Refractory Immune Thrombocytopenia (ITP)

CONTENTS:

• COVID-19 Vaccination in Patients with Immune Thrombocytopenia
• Prednisone Plus IVIG Compared with Prednisone or IVIG For Immune Thrombocytopenia in Pregnancy: A National Retrospective Cohort Study

CONTENTS:

• A Single-Arm, Long-Term Efficacy and Safety Study of Subcutaneous Romiplostim (Nplate®) in Children with Immune Thrombocytopenia
• Risks of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and Bleeding After Covid-19: Nationwide Self-Controlled Cases Series and Matched Cohort Study

CONTENTS:

• Women with Bleeding Disorders: Results from Haemnet’s Cinderella Study
• Prolonged Responses After Discontinuing Thrombopoietin-Receptor Agonists Treatment in ITP: Results from the Multicenter Interventional Study (STOPAGO)

CONTENTS:

• Refractory Immune Thrombocytopenia in Adults: Therapeutic Strategies Inside and Out of the COVID-19 Pandemic
• Switching To Avatrombopag (Doptelet) Following Eltrombopag (Promacta/Revolade) And/Or Romiplostim (Nplate) Use

CONTENTS:

• Differentiating Pediatric Immune Thrombocytopenia (ITP) from Secondary Disorders such as Primary Immune Deficiency (PID) and Inherited Platelet Disorders (IPD)
• The Efficacy and Safety of Different Dosages of Rituximab for Adults With ITP

CONTENTS:

• Do Splenectomized Immune Thrombocytopenia (ITP) Patients Have Increased Risks for Platelet Decreases Following COVID-19 Vaccination?
• Pediatric Patients with ITP Have a Dysbiotic (Imbalanced) Gut Microbiome at Time of Diagnosis